Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A system that detects the formation of complexes between different proteins by linking them to separate domains of the
GAL4
transcription activator protein has been used to study protein-protein interactions between four essential and unique subunits of yeast RNA polymerase III (C82, C53, C34 and C31), the 70-kDa component of the initiation transcription factor IIIB (TFIIIB70) and the
TATA-binding protein
. We found that C82, C34, and C31 are able to combine with each other in vivo and that C34 interacts with TFIIIB70. These results suggest that C34 and TFIIIB70 are specificity determinants of the RNA polymerase III-TFIIIB interaction.
...
PMID:Interaction between a complex of RNA polymerase III subunits and the 70-kDa component of transcription factor IIIB. 840 94
Human transcription factor TFIIB, a protein of 316 amino acids, was subjected to limited proteolysis in order to define stable structural domains. We find that the C-terminal region of TFIIB, residues 106-316, is relatively stable, while the N-terminal region is very sensitive to proteases. Like full-length TFIIB, the stable domain, which we refer to as TFIIBc, interacts with the
TATA-binding protein
(
TBP
) on DNA. However, TFIIBc is unable to substitute for TFIIB in an in vitro transcription assay. We show by gel mobility-shift experiments that TFIIBc arrests formation of the transcription complex after binding to
TBP
, and we conclude that the N-terminal region of TFIIB, which is missing from TFIIBc, is responsible for the recruitment of RNA polymerase II to the promoter. We also show that TFIIBc inhibits transcription by competing with full-length TFIIB for the interaction with
TBP
, either in the presence or in the absence of the
TBP
-associated factors. The acidic transcriptional activator
GAL4
-VP16 does not favor the assembly of the functional transcription complex over the nonfunctional complex containing TFIIBc. Thus, if the function of
GAL4
-VP16 is enhancement of the interaction between TFIIB and the TFIID-DNA complex, then this function can also be exerted on the protease-resistant domain TFIIBc.
...
PMID:Delineation of two functional regions of transcription factor TFIIB. 851 11
The expression of Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA3C) is essential for the activation and immortalization of human B lymphocytes by EBV. EBNA3C consists of 992 amino acids and includes a potential bZIP motif and regions rich in acidic, proline, and glutamine residues. Thus, EBNA3C resembles several trans regulators of gene expression. It has recently been shown that a fragment of EBNA3C can activate reporter gene expression when fused to the DNA-binding domain of
GAL4
(D. Marshall and C. Sample, J. Virol. 69:3624-3630,1995). Although EBNA3C binds DNA, a specific site for EBNA3C binding has not been identified; to test the ability of full-length EBNA3C to regulate transcription, EBNA3C (amino acids 11 to 992) was fused to the DNA-binding domain of
GAL4
. We show that this fusion protein does not transactivate but rather is a potent repressor of reporter gene expression. Repression is dependent on the dose of
GAL4
-EBNA3C and on the presence of
GAL4
-binding sites within reporter plasmids. Repression is not restricted to B cells nor is it species or promoter specific. Repression is independent of the location of the
GAL4
-binding sites relative to the transcription start site. A fragment of EBNA3C (amino acids 280 to 525) which represses expression in a manner which is nearly identical to that of the full-length protein has been identified; this fragment is rich in acidic and proline residues. A second, less potent repressor region located C terminal to amino acids 280 to 525 has also been identified; this domain is rich in proline and glutamine residues. We also show binding of EBNA3C, in vitro, to the
TATA-binding protein
component of TFIID, and this suggests a mechanism by which EBNA3C may communicate with the basal transcription complex.
...
PMID:Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. 864 76
In this report we described the cloning and characterization of ADA5, a gene identified by resistance to
GAL4
-VP16-mediated toxicity. ADA5 binds directly to the VP16 activation domain but not to a transcriptionally defective VP16 double point mutant. Double mutants with mutations in ada5 and other genes (ada2 or ada3) isolated by resistance to
GAL4
-VP16 grow like ada5 single mutants, suggesting that ADA5 is in the same pathway as the other ADA genes. Further, ADA5 cofractionates and coprecipitates with ADA3. However, an ada5 deletion mutant exhibits a broader spectrum of phenotypes than mutants with null mutations in the other ADA genes. Most interestingly, ADA5 is identical to SPT20 (S.M. Roberts and F. Winston, Mol. Cell. Biol. 16: 3206-3213, 1996), showing that it shares phenotypes with the ADA and SPT family of genes. Of the other SPT genes tested, mutants with mutations in SPT7 and, strikingly, SPT15 (encoding the
TATA-binding protein
) show resistance to
GAL4
-VP16. We present a speculative pathway of transcriptional activation involving the ADA2-ADA3-GCN5-ADA5 complex and the
TATA-binding protein
.
...
PMID:ADA5/SPT20 links the ADA and SPT genes, which are involved in yeast transcription. 864 30
The transcriptional activator p53 is known to interact with components of the general transcription factor TFIID in vitro. To examine the relevance of these associations to transcriptional activation in vivo, plasmids expressing a p53-
GAL4
chimera and Drosophila
TATA-binding protein
(dTBP) were transfected into Drosophila Schneider cells. p53-
GAL4
and dTBP displayed a markedly synergistic effect on activated transcription from a
GAL4
site-containing reporter that was at least 10-fold greater than observed with other activators tested. A mutant p53 previously shown to be defective in both transcriptional activation in vivo and in binding to TBP-associated factors (TAFs) in vitro, although still capable of binding dTBP, did not cooperate with dTBP, suggesting that TAFs may contribute to this synergy. Providing further support for this possibility, transfected dTBP assembled into rapidly sedimenting complexes and could be immunoprecipitated with anti-TAF antibodies. While overexpression of any of several TAFs did not affect basal transcription, in either the presence or the absence of cotransfected dTBP, overexpression of TAFII230 inhibited transcriptional activation mediated by p53-
GAL4
as well as by
GAL4
-VP16 and Sp1. Overexpression of TAFII40 and TAFII60 also inhibited activation by p53-
GAL4
but had negligible effects on activation by
GAL4
-VP16 and Sp1, while TAFII110 did not affect any of the activators. TAF-mediated inhibition of activated transcription could be rescued by high levels of exogenous dTBP, which also restored full synergy. These data demonstrate for the first time that functional interactions can occur in vivo between TBP, TAFs, and p53.
...
PMID:Functional interaction between p53, the TATA-binding protein (TBP), andTBP-associated factors in vivo. 875 30
Regions on the surface of human
TATA-box binding protein
(
TBP
) required for activated transcription in vivo were defined by construction of a library of 89 surface residue mutants with radical substitutions that were assayed for their ability to support activated transcription in vivo, basal transcription in vitro, and TFIIA and TFIIB binding in vitro. Four epitopes were identified in which substitutions in two to four neighboring surface residues greatly inhibited activated transcription in vivo. One epitope in which substitutions inhibited both basal and activated transcription (E284, L287) is the interface between
TBP
and TFIIB. Another (A184, N189, E191, R205) is the recently determined interface between
TBP
and TFIIA. Mutations in residues in this TFIIA interface greatly inhibit activated, but not basal transcription, demonstrating a requirement for the TFIIA-
TBP
interaction for activated transcription in vivo in mammalian cells. The remaining two activation epitopes (
TBP
helix 2 residues R231, R235, R239, plus F250; and G175, C176, P247) are probably interfaces with other proteins required for activated transcription. The library of mutants responded virtually identically to two different types of activators, GL4-E1A and
GAL4
-VP16, indicating that transcriptional activation by different classes of activators requires common interactions with
TBP
.
...
PMID:Radical mutations reveal TATA-box binding protein surfaces required for activated transcription in vivo. 884
The general transcription initiation factor TFIID contains the
TATA-binding protein
(
TBP
) and
TBP
-associated factors (TAFs) implicated in the function of gene-specific activators. Previous studies have indicated that a hamster cell line (ts13) with a point mutation in the TAF(II)250/CCG1 (TAF(II)250) gene shows temperature-sensitive expression of a subset of genes and arrests in late G1 at 39.5 degrees C. Here, we report the identification of cell cycle-specific (G1-specific) genes that appear to be regulated directly through TAF(II)250 both in vivo and in vitro. Transcription rates of several cell cycle-regulatory genes were determined by run-on assays in nuclei from ts13 cells grown at permissive (33 degrees C) and nonpermissive (39.5 degrees C) temperatures. Temperature-dependent differences in transcription rates were observed for cyclin A, D1, and D3 genes. In transient-transfection assays, the human cyclin D1 promoter fused to a luciferase reporter showed a temperature-dependent reduction in activity in ts13 cells but not in parental BHK cells. In in vitro assays, upstream sequence-dependent transcription from the human cyclin D1 promoter was significantly reduced in ts13 nuclear extracts preincubated at 30 degrees C but not in similarly treated BHK nuclear extracts, and transcription in the ts13 extract was restored by addition of an affinity-purified human TFIID. Preincubation of the ts13 nuclear extracts did not affect the function of several
GAL4
-activation domain fusion proteins (
GAL4
-VP16,
GAL4
-p65, and
GAL4
-p53) on either the adenovirus major late or cyclin D1 core promoter bearing
GAL4
sites, further indicating that the effect of the TAF(II)250 mutation is both core promoter and activator specific.
...
PMID:The ts13 mutation in the TAF(II)250 subunit (CCG1) of TFIID directly affects transcription of D-type cyclin genes in cells arrested in G1 at the nonpermissive temperature. 915 27
Biochemical experiments indicate that the general transcription factor IIB (TFIIB) can interact directly with acidic activation domains and that activators can stimulate transcription by increasing recruitment of TFIIB to promoters. For promoters at which recruitment of TFIIB to promoters is limiting in vivo, one would predict that transcriptional activity should be particularly sensitive to TFIIB mutations that decrease the association of TFIIB with promoter DNA and/or with activation domains; i.e., such TFIIB mutations should exacerbate a limiting step that occurs in wild-type cells. Here, we describe mutations on the DNA-binding surface of TFIIB that severely affect both
TATA-binding protein
(
TBP
)-TFIIB-TATA complex formation and interaction with the VP16 activation domain in vitro. These TFIIB mutations affect the stability of the
TBP
-TFIIB-TATA complex in vivo because they are synthetically lethal in combination with
TBP
mutants impaired for TFIIB binding. Interestingly, these TFIIB derivatives support viability, and they efficiently respond to Gal4-VP16 and natural acidic activators in different promoter contexts. These results suggest that in vivo, recruitment of TFIIB is not generally a limiting step for acidic activators. However, one TFIIB derivative shows reduced transcription of
GAL4
, suggesting that TFIIB may be limiting at a subset of promoters in vivo.
...
PMID:Transcriptional activation by TFIIB mutants that are severely impaired in interaction with promoter DNA and acidic activation domains. 937 10
Artificial recruitment of
TATA-binding protein
(
TBP
) to many eukaryotic promoters bypasses DNA-bound activator function. The human immunodeficiency virus type 1 (HIV-1) Tat is an unconventional activator that up-regulates transcription from the HIV-1 long terminal repeat (LTR) through binding to a nascent RNA sequence, TAR. Because this LTR and its cognate activator have atypical features compared to a standard RNA polymerase II (RNAP II) transcriptional unit, the precise limiting steps for HIV-1 transcription and how Tat resolves these limitations remain incompletely understood. We thus constructed human
TBP
fused to the DNA-binding domain of
GAL4
to determine whether recruitment of
TBP
is one rate-limiting step in HIV-1 LTR transcription and whether Tat functions to recruit
TBP
. As a control, we compared the activity of the adenovirus E1b promoter. Our findings indicate that
TBP
tethering to the E1b promoter fully effected transcription to the same degree achievable with the potent
GAL4
-VP16 activator. By contrast,
TBP
recruitment to the HIV-1 LTR, although necessary for conferring Tat responsiveness, did not bypass a physical need for Tat in achieving activated transcription. These results document that the HIV-1 and the E1b promoters are transcriptionally limited at different steps; the major rate-limiting step for E1b is recruitment of
TBP
, while activation of the HIV-1 LTR requires steps in addition to
TBP
recruitment. We suggest that Tat acts to accelerate rate-limiting steps after
TBP
recruitment.
...
PMID:Promoter activity of Tat at steps subsequent to TATA-binding protein recruitment. 937 21
An increasing body of evidence suggests that eukaryotic activators stimulate polymerase II transcription by facilitating the assembly of the functional basal machinery at the promoter. Here we describe experiments that provide added support for the idea that recruitment of
TATA-binding protein
(
TBP
) is a rate-limiting step for transcription activation in mammalian cells. We found that, in human cell lines, recruitment of
TBP
to a promoter, as a
GAL4
-
TBP
fusion protein, can provide a substantial activation of transcription. Activation mediated by the hTBP, tethered to promoter DNA, is strictly dependent upon the presence of a functional TATA element, and it directs faithful transcription initiation. Interestingly,
GAL4
-hTBP activation was not observed from initiator (Inr) -dependent TATA-less promoters. These results suggest that
TBP
binding to DNA is not a rate-limiting step for the initial stages of TFIID recruitment to initiator-dependent TATA-less promoters. Finally, we provide evidence that synergy between
GAL4
-hTBP and defined transcription domains is restricted to activators, such as VP16 and Tat, which are likely to function at steps subsequent to the TFIID recruitment. These findings strengthen the idea that recruitment of
TBP
represents an important mechanism of activation of TATA-dependent promoters, and on the other hand, they suggest that
TBP
-DNA interactions are largely dispensable for specific transcription of initiator dependent TATA-less promoters.
...
PMID:Recruitment of human TBP selectively activates RNA polymerase II TATA-dependent promoters. 963 19
<< Previous
1
2
3
4
Next >>